文献速递胸部肿瘤

ASCL1阳性肺腺癌转录组与表观基因组特征的综合分析

An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1-Positive Lung Adenocarcinomas.
PubMed 文献 · J Thorac Oncol · 2018-08-16

本研究整合多个患者队列的转录组谱和全基因组表观遗传谱(含TCGA数据),刻画ASCL1阳性肺腺癌的临床与分子特征。该亚型多见于吸烟者、通常不伴EGFR突变,与近端增殖型分子亚型重叠,免疫细胞浸润差且PD-L1蛋白均阴性,全基因组DNA低甲基化,ASCL1作为超级增强子驱动的转录主调控因子。

要点

  • ASCL1阳性肺腺癌多见于吸烟者且通常不伴EGFR突变。
  • 该亚型免疫细胞浸润差,所有肿瘤PD-L1蛋白表达均为阴性。
  • ASCL1通过超级增强子介导的转录程序调控增殖、生存和细胞周期。

核心结论

  • ASCL1定义了一个具有独特分子特征的肺腺癌亚组,其通过驱动超级增强子介导的转录程序发挥作用。

研究设计与样本

  • 研究利用多个患者队列的近期转录组谱分析及全基因组表观遗传谱分析(包括TCGA数据)来表征ASCL1阳性肺腺癌。

主要发现

  • ASCL1阳性肺腺癌亚型优先发生于当前或既往吸烟者,且通常不携带EGFR突变。
  • 转录组谱中该亚型与近期提出的近端增殖型分子亚型重叠。
  • ASCL1阳性病例的基因表达谱提示免疫细胞浸润普遍较差,且无肿瘤为PD-L1蛋白表达阳性。
  • 全基因组甲基化分析显示ASCL1阳性病例存在全局DNA低甲基化。
  • ASCL1在ASCL1阳性肺腺癌细胞中与超级增强子相关,ASCL1沉默抑制其他超级增强子相关基因,支持ASCL1作为主转录调控因子。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A subgroup of lung adenocarcinoma shows neuroendocrine differentiation and expression of achaete-scute family bHLH transcription factor 1 (ASCL1), common to high-grade neuroendocrine tumors, small-cell lung cancer and large cell neuroendocrine carcinoma. METHODS: The aim of this study was to characterize clinical and molecular features of ASCL1-positive lung adenocarcinoma by using recent transcriptome profiling in multiple patient cohorts and genome-wide epigenetic profiling including data from The Cancer Genome Atlas. RESULTS: The ASCL1-positive subtype of lung adenocarcinoma developed preferentially in current or former smokers and usually did not harbor EGFR mutations. In transcriptome profiling, this subtype overlapped with the recently proposed proximal-proliferative molecular subtype. Gene expression profiling of ASCL1-positive cases suggested generally poor immune cell infiltration and none of the tumors were positive for programmed cell death ligand 1 protein expression. Genome-wide methylation analysis showed global DNA hypomethylation in ASCL1-positive cases. ASCL1 was associated with super-enhancers in ASCL1-positive lung adenocarcinoma cells, and ASCL1 silencing suppressed other super-enhancer-associated genes, suggesting that ASCL1 acts as a master transcriptional regulator. This was further reinforced by the essential roles of ASCL1 in cell proliferation, survival, and cell cycle control. CONCLUSIONS: These results suggest that ASCL1 defines a subgroup of lung adenocarcinoma with distinct molecular features by driving super-enhancer-mediated transcriptional programs.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Miyashita N, Horie M, Suzuki HI, et al. An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1-Positive Lung Adenocarcinomas. J Thorac Oncol. 2018. PMID: 30121393. doi:10.1016/j.jtho.2018.07.096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。